CBP just announced that now all FDA-regulated products must be submitted with appropriate data sets regardless of de minimis value. With increased global reciprocal tariffs potentially around the corner, could this signal a broader de minimis prohibition?

Listen to our Podcast

Copyright © 2025 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.

Professional

avatar
Lenny P. Feldman
Managing Partner, Operating Committee
Close

Cookie Consent

We have updated our Privacy Policy relating to our use of cookies on our website and the sharing of information. By continuing to use our website or subscribe to our publications, you agree to the Privacy Policy and Terms & Conditions.